SUMMARY In-vitro studies of superoxide (Q2) anion production by blood monocytes after stimulation with either serum treated zymosan (STZ), IgG treated zymosan (IgGTZ), or fluoride ion (F-) were performed on cells from normal controls (n=22) and patients with classical or definite rheumatoid arthritis (RA) (n=35). Twenty-two of the patients were on nonsteroidal antiinflammatory drugs (NSAID) alone and 13 were on either sodium aurothiomalate, penicillamine, corticosteroids, or a combination. Monocytes from RA patients on 'second-line therapy' showed significantly increased rates of°Q release in response to STZ compared with normal controls, but no increase was seen in monocytes from patients on NSAID alone. With IgGTZ as the stimulus, rates of 0°release were increased in monocytes from patients on NSAID alone compared with normal controls (p<002), but were increased to a greater extent in monocytes from patients on second-line therapy (p<001). There were no differences in basal unstimulated°Q production and no differences after stimulation with F-. The enhanced release of°Q by monocytes from patients on second-line therapy could not be attributed to increased disease activity and may be an effect of therapy.
Mononuclear phagocytes, which include tissue macrophages and their precursors, blood monocytes, are thought to play an important role in chronic inflammation. Rheumatoid synovium contains numerous mononuclear phagocytes' which are a potential source of a variety of secretory products, including neutral proteases, lysosomal acid hydrolases, prostaglandins, leukotrienes, complement components, and oxygen-free radicals.2 Oxygen-free radicals, which include superoxide anion (0°), hydroxyl radical (OH-), and singlet oxygen (102), make an important contribution not only to host defence against infection 3 and tumour cells4 but also against the tissue damage which may accompany inflammatory and immunological processes.26-8 Furthermore, in RA there is biochemical evidence of free radical mediated oxidative damage, which includes reduced Accepted for publication 4 February 1983. Correspondence to Dr N. P. Hurst, Rheumatic Diseases Unit, Northern General Hospital, Ferry Road, Edinburgh EH5 2DQ. availability of serum-free thiol groups, reduced levels of superoxide dismutase in erythrocytes,9 and the presence of free radical oxidation products of lipids. 10 In-vitro studies have also emphasised the potential role of oxygen-free radicals in damage to connective tissue constituents, including hyaluronic acid'1 and collagen. 12 Phagocytosis of immune complexes by mononuclear phagocytes is a potential stimulus to oxygen-free radical release in RA, but the phagocytic event is not a necessary prerequisite for free radical generation, and the processes are functionally distinct.13 14 Various soluble stimuli, including C5a,"4 15 can activate oxygen-free radical release, while others, including lymphokines"6 and proteases,7 18 can enhance or 'prime' the free radical responses of phagocytes.
The capacity of mononuclear phagocytes from patients with RA to generate oxygen-free radicals has not been widely studied, and as part of an investigation of the role of the mononuclear phagocyte in 28 RA we have compared 0 production by blood monocytes from normal controls and patients with classical or definite RA.
Materials and methods
Subjects. Twenty-two healthy hospital and laboratory employees (11 male, 11 female; mean age 40-2+ (SD) 13 3 years and 35 patients with classical or definite RA were studied."9 Twenty-two of these patients were taking NSAID alone (n=21) or no antirheumatic therapy (n=1) (11 male, 11 female; mean age 51 4+ 16-6 years), and 13 patients (7 male, 6 female; mean age 50 9± 12-9 years) were taking either sodium aurothiomalate (n=3) (total dose 0-6-1-05 g), penicillamine (n=4) ( Stimulated superoxide anion production In the presence of fluoride ion a 6-fold increase in rates of 0; production over basal levels occurred, but there were no differences between any of the groups studied (Fig. 1) .
With IgTZ, rates of 0; production were significantly increased in monocytes from RA patients on 'second-line therapy' (p<0. 01) and to a lesser extent in monocytes from RA patients on NSAID alone (p<0 02) compared with normal controls (Fig. 1) .
With STZ significant enhancement of 0; generation was seen in monocytes from patients on secondline therapy (p<0001) compared with normal con- trols, but no enhancement was seen in monocytes from patients on NSAID alone (Fig. 1) .
Correlation of in vitro rates of 0; production with disease activity No significant differences in monocyte 0; production were found between patients with mild or inactive disease, moderately active disease, or very active disease (Fig. 2) . Furthermore, although patients or second-line therapy had higher rates of in-vitro monocyte 0; production, they had a lower mean clinical score (2-9± 2 5) than those on NSAID alone (43±+1*7). These differences are not statistically significant.
As there was no significant difference in mean values for superoxide production in patients under treatment with gold, penicillamine, or corticosteroid drugs, the results have been analysed as a combined 'second-line therapy' group in each case.
Discussion
These results suggest that monocytes from some RA patients have enhanced capacity to generate 0; in response to immunological stimuli but not to a soluble biochemical stimulus such as fluoride ion. An increase in rates of 0; release was found primarily with monocytes from patients on second-line therapy and was more marked after stimulation with STZ, a combined C3b/Fc receptor stimulus, than with IgTZ, which stimulates Fc receptors alone. No comparable increase in basal unstimulated release of 0; was seen, suggesting that these differences were not due to immune complexes binding to monocyte receptors and causing prior stimulation. Furthermore, the differences were entirely attributable to enhanced 0; release, since there was no change in levels of 'nondismutase inhibitable' reducing activity.
Enhanced extracellular release of H202 and 0; by mononuclear phagocytes is seen both after stimulation in vitro with lymphokines and after antigenic stimulation in vivo with BCG or Corynebacterium parvum. 16 26 It has been suggested that such augmentation of oxidative metabolism is a feature of mononuclear phagocyte activation,26 and it is therefore of considerable interest that this phenomenon should be identified in monocytes from patients with RA.
In our patients a number of factors might be responsible for enhancement of 0; release and include disease activity, an effect of second-line therapy or conceivably loss of inhibition of 0; production after reduction of NSAID intake by patients on second-line therapy. Mechanisms by which this could occur include changes in monocyte receptor expression, enhancement of intracellular NADPH production, or, by reduction of NSAID intake, removal of potential inhibitors of 0; production. group.bmj.com on June 26, 2017 -Published by http://ard.bmj.com/ Downloaded from data from a prospective study of patients before and after beginning second-line therapy27 the most likely cause of monocyte activation in these patients is the introduction of second-line therapy. Our data do not suggest that enhanced 02 release is secondary to disease activity or to withdrawal of NSAID.
Altered receptor expression seems the most likely mechanism for the effect, since differences in 02 release were seen with opsonised zymosan but not with F-, a biochemical stimulus. The observations of previous workers using rosetting techniques on monocytes from RA patients who found enhanced Fc receptor expression,28 29 and others30 who found increased antibody dependent cellular cytotoxicity (ADCC), lend support to this view. Furthermore, since ADCC may be mediated by oxygen free radicals,3" our data provide a biochemical mechanism for such an increase in functional activity. The in-vivo effects of penicillamine and sodium aurothiomalate on monocyte receptor expression in RA do not appear to have been studied, so direct enhancement of receptor expression by these drugs cannot be excluded. On the other hand there is evidence that sodium aurothiomalate and penicillamine raise intracellular levels of glutathione and SOD,32 and this might secondarily increase levels of NADPH, the key substrate for 03 production. Since we cannot preclude the possibility that stimulation with F-was too insensitive to detect differences in rates of 0; generation, a biochemical rather than an immunological mechanism could also account for enhancement of 0; production.
In conclusion, our The manual deals with writing in all the biological sciences, but most of it is relevant to medicine. It offers sound advice about the ethical aspects of authorship and publication; preparation of manuscripts, tables, and illustrations; prose style, including a list ofcommon errors; technical style conventions; indexing; proof correction; refereeing ('Test the critique for fairness and objectivity by asking yourself if you would be willing to sign it and send it to the author'). The style of the manual itself is North American, but throughout it draws attention to differences between British and American usage, and these comparisons make interesting reading. The authors might have commented on how the simpler North American spelling avoids that most common error in British medical writing, the insertion of an inappropriate diphthong (as in thrombocytopaenia for thrombocytopenia). All in all, this is an excellent publication: concise, yet comprehensive and entertaining. I recommend it. 
